EUCTR2024-000422-17-Outside-EU/EEA进行中（未招募）1 期
A PHASE 1, OPEN-LABEL, AGE DESCENDING, DOSE-FINDING STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF RESPIRATORY SYNCYTIAL VIRUS PREFUSION F SUBUNIT VACCINE (RSVpreF) IN CHILDREN 2 TO <18 YEARS OF AGE
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- Pfizer Inc.
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •1) Participants 2 to <18 years of age at enrollment
- •2) Participants 2 to <18 years of age should either be healthy or be considered by the investigator to be at high risk of RSV disease based on the presence of 1 of the following chronic medical conditions:
- •Cystic fibrosis
- •Medically treated asthma
- •Other chronic respiratory diseases and malformations of the lung
- •Down syndrome
- •Neuromuscular disease
- •Cerebral palsy
- •Hemodynamically significant or symptomatic congenital heart disease
- •3. All participants 2 to <5 years of age must be seropositive for RSV as confirmed by serology.
- •4. Participants' parent(s)/legal guardian(s) and participants, as age appropriate, who are willing and able to comply with all scheduled visits, investigational plan, laboratory tests, and other study procedures, including collection of nasal swabs by participants' parent(s)/legal guardian(s) and by study staff when indicated.
- •5. The participant's parent(s)/legal guardian is capable of giving signed informed consent as described in the protocol. Depending on the age of the participant and according to local requirements, participants will also be asked to provide assent as appropriate (verbal or written).
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range: 121
- •F.1.2 Adults (18-64 years) no
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1) Immunocompromised individuals associated with known or suspected immunodeficiency, as determined by history and/or laboratory/physical examination.
- •2) Individuals with a history of autoimmune disease or an active autoimmune disease requiring therapeutic intervention, including but not limited to systemic lupus erythematosus. Note: Stable type 1 diabetes and hypothyroidism are permitted.
- •3) Other medical or psychiatric condition including recent (within the past year) or active suicidal ideation/behavior or laboratory abnormality that may increase the risk of study participation or, in the investigator's judgment, make the participant inappropriate for the study.
- •4) History of severe adverse reaction associated with a vaccine and/or severe allergic reaction (eg, anaphylaxis) to any component of the study intervention(s).
- •5) Bleeding diathesis or condition associated with prolonged bleeding that would, in the opinion of the investigator, contraindicate intramuscular injection.
- •6) Individuals with a history of epilepsy or other seizure disorders, or a history of seizures and/or other neurological complications following vaccination.
- •7) Previous vaccination with any licensed or investigational RSV vaccine or planned receipt during study participation. Children who may have been exposed to investigational RSV vaccines through maternal immunization will be permitted.
- •8) Receipt of investigational or approved monoclonal antibodies against RSV within 6 months before study intervention administration, or planned receipt throughout the study.
- •9) Receipt of blood/plasma products or immunoglobulins within 28 days before study intervention administration, or planned receipt throughout the study.
- •10) Receipt of chronic systemic treatment with known immunosuppressant medications (including cytotoxic agents or systemic corticosteroids), or radiotherapy, within 60 days before study intervention administration, or planned receipt throughout the study.
- •Note: Systemic corticosteroids are defined as those administered for =14 days at a dose of =20 mg/day of prednisone or equivalent (eg, for cancer or an autoimmune disease). Inhaled/nebulized, intra-articular, intrabursal, or topical (skin, eyes, or ears) corticosteroids are permitted.
- •11) Participation in other studies involving study intervention within 28 days prior to study entry and/or for the duration of study participation.
- •12) Investigator site staff directly involved in the conduct of the study and their family members, site staff otherwise supervised by the investigator, and sponsor and sponsor delegate employees directly involved in the conduct of the study and their family members.
研究者
相似试验
Unknown
1 期
A study to determine if a new malaria vaccine is safe and induces immunity among Kenyan adults, young children and infants.MalariaPACTR202105682956280niversity of Oxford91
已完成
1 期
Phase I Study of TAS-120 in Patients with Advanced Solid TumorsJPRN-jRCT2080222501Taiho Pharmaceutical Co., Ltd.142
已完成
1 期
A PHASE I, OPEN-LABEL, NON-RANDOMIZED, DOSE-ESCALATING, SAFETY, TOLERABILITY, PHARMACOKINETIC, AND EFFICACY STUDY OF TAS-117 IN PATIENTS WITH ADVANCED SOLID TUMORSPatients with advanced solid tumors, ovarian clear cell carcinoma and endometrial cancer.JPRN-jRCT2080222728Taiho Pharmaceutical Co., Ltd.168
未知
1 期
A PHASE I, OPEN-LABEL, NON-RANDOMIZED, DOSE-ESCALATING, SAFETY, TOLERABILITY, PHARMACOKINETIC, AND EFFICACY STUDY OF TAS-121 IN PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC)SCLCJPRN-jRCT2080222600Taiho Pharmaceutical Co., Ltd.
进行中（未招募）
1 期
Study to Assess the Pharmacokinetics, Safety, and Tolerability of Pimavanserin in Adolescents with Psychiatric DisordersPsychiatric DisordersMedDRA version: 20.0Level: SOCClassification code 10037175Term: Psychiatric disordersSystem Organ Class: 10037175 - Psychiatric disordersMedDRA version: 20.0Level: HLTClassification code 10037177Term: Infancy, childhood and adolescence psychiatric disorders NECSystem Organ Class: 10037175 - Psychiatric disordersEUCTR2018-001064-30-BGACADIA Pharmaceuticals Inc.36